CHARLESTON, W.Va., Dec. 7 /PRNewswire-FirstCall/ -- Schering-Plough Corporation today reported that a jury has ruled in favor of the company in a West Virginia trial related to reimbursement by West Virginia's Medicaid program of certain asthma products sold by Warrick Pharmaceuticals, the company's generic subsidiary. In the favorable verdict, the jury agreed with company's position that in connection with reporting Average Wholesale Price (AWP), the company complied with all applicable laws and regulations governing the reimbursement rules in West Virginia.
Schering-Plough is pleased with the positive jury verdict in this case and looks forward to continuing to put litigation matters from the past behind it. This matter has been disclosed in the company's SEC filings.
Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its 30,000 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.
102-1205
Schering-Plough CorporationCONTACT: Media - Denise Foy, +1-908-298-7616, or Investor - Alex Kelly,+1-908-298-7436, both of Schering-Plough Corporation
Web site: http://www.schering-plough.com/
Company News On-Call: http://www.prnewswire.com/comp/777050.html /
